Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESLANASDAQ:NLTXNASDAQ:SLSNASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESLAEstrella Immunopharma$1.12+0.9%$0.95$0.63▼$3.23$40.51M0.4184,847 shs57,085 shsNLTXNeoleukin Therapeutics$13.05-13.6%$13.58$2.03▼$14.36$32.80M1.1150,104 shs652,993 shsSLSSELLAS Life Sciences Group$1.71-0.6%$1.25$0.77▼$1.85$161.68M2.341.39 million shs1.31 million shsTNGXTango Therapeutics$1.15-8.7%$1.54$1.11▼$12.02$124.32M1.021.08 million shs348,205 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESLAEstrella Immunopharma-1.80%+1.34%+26.10%+1.34%+10.97%NLTXNeoleukin Therapeutics-10.96%+4.21%+71.90%-16.40%-53.95%SLSSELLAS Life Sciences Group+0.58%+20.28%+65.38%+14.67%+33.33%TNGXTango Therapeutics-11.27%-7.35%-0.79%-62.39%-84.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationESLAEstrella Immunopharma2.1675 of 5 stars3.55.00.00.00.61.70.0NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group0.9053 of 5 stars0.04.00.00.03.20.00.6TNGXTango Therapeutics2.0269 of 5 stars3.50.00.00.03.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESLAEstrella Immunopharma 3.00Buy$16.001,328.57% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 0.00N/AN/AN/ATNGXTango Therapeutics 3.00Buy$12.33972.46% UpsideCurrent Analyst Ratings BreakdownLatest ESLA, TNGX, SLS, and NLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025TNGXTango TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.002/18/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$16.00 ➝ $16.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ASLSSELLAS Life Sciences Group$1M161.68N/AN/A($0.25) per share-6.84TNGXTango Therapeutics$42.07M2.96N/AN/A$2.48 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-195.77%-157.28%5/13/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ASLSSELLAS Life Sciences Group-$37.34M-$0.52N/AN/AN/AN/A-629.46%-178.65%5/13/2025 (Estimated)TNGXTango Therapeutics-$101.74M-$1.21N/AN/AN/A-284.42%-49.64%-32.00%5/12/2025 (Estimated)Latest ESLA, TNGX, SLS, and NLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067N/AN/AN/AN/AN/A5/12/2025Q1 2025TNGXTango Therapeutics-$0.34N/AN/AN/A$6.73 millionN/A3/20/2025Q4 2024SLSSELLAS Life Sciences Group-$0.1067-$0.08+$0.0267-$0.08N/AN/A2/27/2025Q4 2024TNGXTango Therapeutics-$0.32-$0.35-$0.03-$0.35$7.84 million$4.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESLAEstrella ImmunopharmaN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESLAEstrella ImmunopharmaN/A0.750.75NLTXNeoleukin TherapeuticsN/A15.3315.33SLSSELLAS Life Sciences GroupN/A2.262.26TNGXTango TherapeuticsN/A8.008.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESLAEstrella Immunopharma0.35%NLTXNeoleukin Therapeutics52.37%SLSSELLAS Life Sciences Group17.38%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipESLAEstrella Immunopharma55.10%NLTXNeoleukin Therapeutics1.58%SLSSELLAS Life Sciences Group1.20%TNGXTango Therapeutics6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataSLSSELLAS Life Sciences Group1094.55 million69.54 millionNot OptionableTNGXTango Therapeutics90108.11 million100.65 millionOptionableESLA, TNGX, SLS, and NLTX HeadlinesRecent News About These CompaniesTango Therapeutics (TNGX) to Release Quarterly Earnings on MondayMay 7 at 10:21 AM | marketbeat.comTango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseMay 5 at 11:05 AM | zacks.comBoxer Capital Management LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 4 at 6:25 AM | marketbeat.comSusquehanna Fundamental Investments LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 4 at 4:35 AM | marketbeat.comTCG Crossover Management LLC Invests $33.17 Million in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 1, 2025 | marketbeat.comTango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 1, 2025 | globenewswire.comNantahala Capital Management LLC Invests $8.67 Million in Tango Therapeutics, Inc. (NASDAQ:TNGX)April 30, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Trims Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)April 30, 2025 | marketbeat.comWhy Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 5.37%April 29, 2025 | aaii.comBlue Owl Capital Holdings LP Acquires New Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)April 26, 2025 | marketbeat.comTrv Gp Vi LLC Acquires New Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)April 22, 2025 | marketbeat.comGilead Sciences Inc. Acquires Shares of 4,854,443 Tango Therapeutics, Inc. (NASDAQ:TNGX)April 20, 2025 | marketbeat.comHC Wainwright Brokers Reduce Earnings Estimates for TNGXApril 18, 2025 | marketbeat.comQ1 Earnings Forecast for TNGX Issued By HC WainwrightApril 17, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Buy" from AnalystsApril 16, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Tango Therapeutics (NASDAQ:TNGX)April 16, 2025 | marketbeat.comBarbara Weber, M.D., Elected to ITM Supervisory BoardApril 9, 2025 | markets.businessinsider.comTango Therapeutics cuts nearly one-fifth of staffApril 8, 2025 | biopharmadive.comSchroder Investment Management Group Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)April 8, 2025 | marketbeat.comTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at [...]March 25, 2025 | aktiencheck.deTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025March 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTesla Stock Eyes Breakout With Earnings on DeckBy Sam Quirke | April 16, 2025View Tesla Stock Eyes Breakout With Earnings on DeckTesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedBy Sam Quirke | April 30, 2025View Tesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedTesla’s #1 Bull Cuts Target But Says It’s Still a BuyBy Sam Quirke | April 8, 2025View Tesla’s #1 Bull Cuts Target But Says It’s Still a BuyXPeng Deliveries Surge 3X in China, Should Tesla Be Worried?By Jea Yu | April 11, 2025View XPeng Deliveries Surge 3X in China, Should Tesla Be Worried?Tesla Earnings Miss, But Musk Refocuses and Bulls ReactBy Sam Quirke | April 23, 2025View Tesla Earnings Miss, But Musk Refocuses and Bulls ReactESLA, TNGX, SLS, and NLTX Company DescriptionsEstrella Immunopharma NASDAQ:ESLA$1.12 +0.01 (+0.48%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Neoleukin Therapeutics NASDAQ:NLTX$13.05 -2.06 (-13.63%) As of 05/6/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.SELLAS Life Sciences Group NASDAQ:SLS$1.71 -0.01 (-0.58%) Closing price 04:00 PM EasternExtended Trading$1.70 -0.01 (-0.58%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Tango Therapeutics NASDAQ:TNGX$1.15 -0.11 (-8.73%) Closing price 04:00 PM EasternExtended Trading$1.16 +0.01 (+0.87%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
